Scholar Rock FY2027 EPS Forecast Raised by HC Wainwright

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Research analysts at HC Wainwright raised their FY2027 earnings estimates for shares of Scholar Rock in a note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($2.28) for the year, up from their prior estimate of ($2.39). HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2028 earnings at ($0.92) EPS and FY2029 earnings at $0.17 EPS.

Several other research analysts have also commented on SRRK. Citigroup began coverage on shares of Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 price objective for the company. Wolfe Research initiated coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Truist Financial reduced their price objective on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, October 20th. Finally, Barclays boosted their target price on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.14.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $44.92 on Wednesday. The business’s 50 day moving average price is $44.18 and its 200-day moving average price is $37.51. Scholar Rock has a fifty-two week low of $22.71 and a fifty-two week high of $48.28. The company has a market cap of $4.58 billion, a P/E ratio of -14.26 and a beta of 0.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period in the prior year, the company earned ($0.66) earnings per share.

Insider Buying and Selling

In other news, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,438.50. Following the transaction, the chief financial officer owned 583,245 shares of the company’s stock, valued at approximately $24,904,561.50. This represents a 2.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mo Qatanani sold 136,462 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02. Following the transaction, the insider owned 108,964 shares in the company, valued at approximately $4,926,262.44. This represents a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 305,687 shares of company stock valued at $13,540,573 over the last 90 days. 13.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Scholar Rock by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after purchasing an additional 280,538 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Scholar Rock by 28.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,622 shares of the company’s stock worth $952,000 after buying an additional 4,772 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Scholar Rock by 5.5% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 168,547 shares of the company’s stock worth $7,424,000 after buying an additional 8,806 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Scholar Rock by 33.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,957 shares of the company’s stock valued at $218,000 after acquiring an additional 1,241 shares in the last quarter. Finally, CWM LLC increased its holdings in shares of Scholar Rock by 2,351.2% in the 4th quarter. CWM LLC now owns 9,584 shares of the company’s stock valued at $422,000 after acquiring an additional 9,193 shares during the period. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).